La catena delle opzioni mostra i dati chiave delle opzioni azionarie di MFA Financial, Inc. 8.875% Senior Notes due 2029 a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per MFA Financial, Inc. 8.875% Senior Notes due 2029..

MFA Financial, Inc. 8.875% Senior Notes due 2029 (NYSE:MFAN) Azioni, Catena delle Opzioni

MFA Financial, Inc. 8.875% Senior Notes due 2029

Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) FY2025 expected to be more than $5.00 vs $4.92 Est. FY2025 Revenue expected to be more than $6.95B vs $6.87B Est

News

Guidance

Tapestry FY2025  expected to be more than $5.00 vs $4.92 Est; FY2025  Revenue expected to be more than $6.95B vs $6.87B Est

Earnings

Chimera Investment Q1 Adj. EPS $0.41 Beats $0.40 Estimate, Sales $69.22M Miss $72.07M Estimate

Financial Outlook
As of March 30, 2025, Krispy Kreme doughnuts are now available in more than 2,400 McDonald's restaurants. The Company is reassessing the deployment schedule together with McDonald's while it works to achieve a profitable business model for all parties and does not expect to launch in any additional restaurants in the second quarter of 2025.
Krispy Kreme continues to believe in the long-term opportunity of profitable growth through the U.S. nationwide expansion including McDonald's.
Given macroeconomic softness and the uncertainty around the McDonald's deployment schedule, the Company is withdrawing its prior full year outlook and not updating it at this time. Regarding the second quarter of 2025, the Company expects to deliver:
<ul>
<li>Net Revenue of $370 to $385 million</li>
<li>Adjusted EBITDA(1) of $30 to $35 million</li>
</ul>

DNUT

Krispy Kreme Sees Q2 Sales $370.000M-$385.000M vs $393.85M Est

WIIM

WRBY

Warby Parker shares are trading lower after the company missed Q1 estimates and lowered its FY25 sales guidance.

PLNT

Planet Fitness shares are trading lower after the company missed Q1 estimates and reaffirmed FY25 guidance below expectations.

Brookfield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BN#NYSE">BN</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.90 by 8.89 percent. This is a 27.27 percent increase over earnings of $0.77 per share from the same period last year. The company reported $17.94 billion in sales this quarter. This is a 21.67 percent decrease over sales of $22.91 billion the same period last year.

Earnings Beats

Brookfield Q1 Adj. EPS $0.98 Beats $0.90 Estimate, Sales $17.94B Down From $22.91B YoY

Restaurant Brands shares are trading lower after the company reported Q1 results below estimates.

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4422918-1&amp;h=3767541836&amp;u=https%3A%2F%2Fwww.viatris.com%2Fen&amp;a=Viatris+Inc.">Viatris Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>), a global healthcare company, today announced positive results of its Phase 3 study (NCT05139121) evaluating the contraceptive efficacy and safety of investigational XULANE LO low dose weekly dermal patch of 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol per day in women of childbearing potential. The study evaluated women of childbearing potential (N=1,272) for up to 13 cycles (12,591 safety evaluable cycles and 9,105 efficacy evaluable cycles) across 81 investigative sites throughout the U.S., Puerto Rico and Canada.
In this study, XULANE LO demonstrated a favorable efficacy and safety profile with no new safety concerns identified as well as a potential best-in-class patch performance profile. In particular:
<ul>
<li>With a Pearl Index (PI) of 4.14, the study demonstrated contraceptive efficacy. This primary efficacy endpoint was measured in eligible women aged 16 to 35 with a body mass index &lt;30 mg/m2 and at least one efficacy evaluable cycle. Additionally, the cumulative probability of pregnancy over 13 cycles was 3.7%. &nbsp;</li>
<li>A favorable safety and tolerability profile was observed with most treatment emergent adverse events (TEAEs) reported as mild-to-moderate. Favorable cycle control was also observed with generally low unscheduled bleeding and spotting events. &nbsp;</li>
<li>The study demonstrated a potential best-in-class patch adhesion profile with very few patches (1.3%) completely detaching over the seven-day wearing period and &lt;1% of subjects reporting severe local application site reactions.</li>
</ul>

VTRS

Viatris Reports Phase 3 Results for Low-Dose Birth Control Patch With Strong Safety Profile

Nomad Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOMD#NYSE">NOMD</a>) raises FY2025 Adj EPS guidance from $1.94-$1.98 to $2.07-$2.15 vs $1.88 analyst estimate..

NOMD

Nomad Foods Raises FY2025 Adj EPS Guidance from $1.94-$1.98 to $2.07-$2.15 vs $1.88 Est

Canaccord Genuity analyst Joseph Vafi maintains Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) with a Buy and maintains $8 price target.

Price Target

Analyst Ratings

CIFR

Canaccord Genuity Maintains Buy on Cipher Mining, Maintains $8 Price Target

Management

Valvoline Announced That Kevin Willis Will Succeed Mary Meixelsperger As New Chief Financial Officer Effective May 19

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck &amp; Co., Inc., Rahway, N.J., USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and Kansas Governor Laura Kelly jointly announced today the $895 million expansion of Merck Animal Health's manufacturing facility in De Soto, Kansas.
The $895 million capital expansion will be constructed on an existing Merck-owned property that is the site of its biologics facility in De Soto, Kansas. It includes an $860 million investment in the site's existing manufacturing facility and a further $35 million investment in its research and development laboratories.
The 200,000-square-foot manufacturing facility project will expand filling and freeze dryer capacity for large molecule vaccines and biologic products for Merck Animal Health. As a Center of Excellence, it will play a pivotal role in the manufacturing of Merck Animal Health's products and will complement Merck Animal Health's extensive U.S. and international network of animal health product manufacturing plants.
Site preparation and facility design will start immediately, creating 2,500 construction jobs. Commercial manufacturing is expected to begin in 2030, creating more than 200 full-time roles.
Merck Animal Health's significant investment in its research and development laboratories will enhance its research capabilities, focusing on advancing Merck Animal Health's global drug discovery and development initiatives. The investment will continue to drive Merck Animal Health's innovative research and development of novel parasiticides and therapeutics, reinforcing the company's dedication to improving animal health and welfare worldwide.

Merck Animal Health Plans $895M Expansion in Kansas, Adding Jobs and Boosting Vaccine Production

Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $0.88 by 17.05 percent. This is a 27.16 percent increase over earnings of $0.81 per share from the same period last year. The company reported quarterly sales of $1.58 billion which beat the analyst consensus estimate of $1.53 billion by 3.80 percent. This is a 6.95 percent increase over sales of $1.48 billion the same period last year.

Tapestry Q3 Adj. EPS $1.03 Beats $0.88 Estimate, Sales $1.58B Beat $1.53B Estimate

US Foods Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) affirms FY2025 Adj EPS guidance from $3.69-$3.88 to $3.69-$3.88 vs $3.79 analyst estimate. Affirms FY2025 sales outlook from $39.39 billion-$40.15 billion to $39.39 billion-$40.15 billion vs $39.75 billion estimate.

USFD

US Foods Hldg Affirms FY2025 Adj EPS Guidance of $3.69-$3.88 vs $3.79 Est; Affirms FY2025 Sales Guidance of $39.39B-$40.15B vs $39.75B Est

International Seaways (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSW#NYSE">INSW</a>) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.62 by 29.03 percent. This is a 72.6 percent decrease over earnings of $2.92 per share from the same period last year. The company reported quarterly sales of $183.39 million which beat the analyst consensus estimate of $174.47 million by 5.11 percent. This is a 33.17 percent decrease over sales of $274.40 million the same period last year.

INSW

International Seaways Q1 Adj. EPS $0.80 Beats $0.62 Estimate, Sales $183.39M Beat $174.47M Estimate

Warby Parker Lowers FY2025 Sales Guidance from $878.00M-$893.00M to $869.00M-$886.00M vs $883.46M Est

Nomad Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOMD#NYSE">NOMD</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.35 by 5.71 percent. This is a 7.5 percent decrease over earnings of $0.40 per share from the same period last year. The company reported quarterly sales of $799.33 million which beat the analyst consensus estimate of $767.12 million by 4.20 percent. This is a 6.09 percent decrease over sales of $851.14 million the same period last year.

Nomad Foods Q1 Adj. EPS $0.37 Beats $0.35 Estimate, Sales $799.33M Beat $767.12M Estimate

Krispy Kreme (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNUT#NASDAQ">DNUT</a>) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 171.43 percent decrease over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $375.18 million which missed the analyst consensus estimate of $384.38 million by 2.39 percent. This is a 15.25 percent decrease over sales of $442.70 million the same period last year.

Earnings Misses

Krispy Kreme Q1 Adj. EPS $(0.05), Inline, Sales $375.18M Miss $384.38M Estimate

Warby Parker Q1 EPS $0.03 Misses $0.06 Estimate, Sales $223.78M Miss $225.50M Estimate

US Foods Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) reported quarterly earnings of $0.68 per share which missed the analyst consensus estimate of $0.69 by 1.45 percent. This is a 25.93 percent increase over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $9.35 billion which missed the analyst consensus estimate of $9.38 billion by 0.33 percent. This is a 4.49 percent increase over sales of $8.95 billion the same period last year.

Comments

MFA Financial, Inc. 8.875% Senior Notes due 2029

MFA Financial, Inc. 8.875% Senior Notes due 2029 (MFAN) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO